<DOC>
	<DOCNO>NCT02489058</DOCNO>
	<brief_summary>This observational sample collection study involve patient ( alive decease ) several clinical trial receive investigational drug , olaparib research study . There intervention give study . This research do understand mechanism involve patient whose cancer respond well whose cancer respond well investigational drug , olaparib , help good understand olaparib work well identify patient may benefit therapy .</brief_summary>
	<brief_title>A Study Long-Term Responders Olaparib</brief_title>
	<detailed_description>This study compare biomarker research response patient receive olaparib . Patients durable response olaparib least 2 year approach study . Patients agree study medical history collect ask complete questionnaire . Archival tumor tissue also collect biomarker research . A waiver consent request access medical record archival tumor tissue patient decease . If participant still take olaparib , ask provide blood sample pharmacokinetics circulate tumor DNA , result CT scan take part standard care part another research study . If participant ' disease worsens still olaparib , ask provide blood sample pharmacogenomics BRCA testing ( know ) . An optional tumor biopsy also request . Participants continue follow telephone survival new treatment receive .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Previous current treatment Olaparib clinical trial/standard care include one follow first step study epithelial ovarian cancer ( include fallopian tube peritoneal cancer ) : single agent olaparib give relapsed disease single agent olaparib give maintenance therapy response platinum base chemotherapy olaparib combine platinum base chemotherapy continue maintenance therapy olaparib combine type therapy Had durable response Olaparib define patient benefit olaparib 2 year . Patients discontinue Olaparib due toxicity otherwise meet definition durable response include control group patient short duration benefit Olaparib le 3 month individual clinical trial/standard care Ability understand willingness sign write informed consent document . Patient 's willingness ability comply schedule visit , laboratory test , study procedure . Any severe acute chronic medical psychiatric condition laboratory abnormality would render patient unsuitable biopsy Pregnant breastfeeding woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>